Medtronic announced it will exercise its option to acquire Israeli-based CathWorks in a deal valued at up to $585 million, with potential undisclosed earn-out payments upon completion. The transaction builds on a 2022 strategic partnership, under which Medtronic and CathWorks co-promoted the AI-driven FFRangio System across the U.S., Europe and Japan. The angiography-derived system provides fractional flow reserve (FFR) measurements along the entire coronary tree and offers intraprocedural optimization tools, such as lesion sizing and physiological impact assessment. Completion of the deal is subject to U.S. FTC clearance and is expected by the end of Medtronic’s fiscal 2026, with CathWorks operating independently until closing. Medtronic projects the acquisition will be immaterial to its fiscal 2027 GAAP and adjusted earnings per share and neutral to accretive thereafter.

Medtronic’s Diabetes division secured three U.S. milestones: Medicare coverage for its MiniMed 780G system paired with Abbott’s Instinct sensor, FDA clearance for use of ultra-rapid acting insulins Fiasp and Lyumjev, and clearance of the MiniMed 780G system with Instinct sensor for insulin-requiring type 2 diabetes. Medicare beneficiaries can now choose between Instinct, Simplera Sync and Guardian 4 sensors, expanding access to automated insulin delivery that adjusts doses every five minutes. The ultra-rapid insulins enhance post-meal glucose control by reducing time to onset, working in tandem with Meal Detection technology. The type 2 diabetes clearance enables the SmartGuard algorithm and ACE-enabled pump to integrate with Instinct sensor, offering up to 15 days of wear and optimized glycemic management for a broader patient population.